The success of CAR-T therapy directed against CD19 in high-risk hematologic cancers has paved the way for research using modified lymphocytes (primarily T or NK cells) to attack tumor cells. The gene discussed is CD19; the disease is hematopoietic and lymphoid cell neoplasm.